| Company Name: |
Combiphos (Shanghai) Biological Technology Co., Ltd.
|
| Tel: |
021-65232103 17602124823 |
| Email: |
combiphos@vip.qq.com |
| Products Intro: |
Product Name:1-((2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(methyl-d3)pyrimidine-2,4(1H,3H)-dione-6-d
CAS:1134182-00-5
Purity:95% HPLC Package:100 mg
250 mg
500 mg
1.0 g
5.0 g Remarks:DS2921
|
| Company Name: |
TLC PharmaChem Inc.
|
| Tel: |
(905) 268-0252 |
| Email: |
research@tlcpharmachem.com |
| Products Intro: |
|
|
| | Telbivudine-d4 Basic information |
| Product Name: | Telbivudine-d4 | | Synonyms: | Telbivudine-d4;1-((2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(methyl-d3)pyrimidine-2,4(1H,3H)-dione-6-d | | CAS: | 1134182-00-5 | | MF: | C10H14N2O5 | | MW: | 242.23 | | EINECS: | | | Product Categories: | | | Mol File: | 1134182-00-5.mol |  |
| | Telbivudine-d4 Chemical Properties |
| | Telbivudine-d4 Usage And Synthesis |
| Uses | Telbivudine-d4 is deuterium labeled Telbivudine. Telbivudine (Epavudine), an orally active thymidine nucleoside analog, is a potent antiviral inhibitor of hepatitis B virus (HBV) replication[1]. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Kim JW, et al. Telbivudine: a novel nucleoside analog for chronic hepatitis B. Ann Pharmacother. 2006;40(3):472-478. DOI:10.1345/aph.1G027
[3] Zobel T, et al. Telbivudine Reduces Parvovirus B19-Induced Apoptosis in Circulating Angiogenic Cells. Viruses. 2019;11(3):227. Published 2019 Mar 6. DOI:10.3390/v11030227 |
| | Telbivudine-d4 Preparation Products And Raw materials |
|